Abstract:Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and the most common single-gene cause of autism. It is caused by mutations on the fragile X mental retardation gene (FMR1) and lack of fragile X mental retardation protein, which in turn, leads to decreased inhibition of translation of many synaptic proteins. The metabotropic glutamate receptor (mGluR) hypothesis states that the neurological deficits in individuals with FXS are due mainly to downstream consequences of overstimulation of the mGluR pathway. The main efforts have focused on mGluR5 targeted treatments; however, investigation on the gamma-aminobutyric acid (GABA) system and its potential as a targeted treatment is less emphasized. The fragile X mouse models (Fmr1-knock out) show decreased GABA subunit receptors, decreased synthesis of GABA, increased catabolism of GABA, and overall decreased GABAergic input in many regions of the brain. Consequences of the reduced GABAergic input in FXS include oversensitivity to sensory stimuli, seizures, and anxiety. Deficits in the GABA receptors in different regions of the brain are associated with behavioral and attentional processing deficits linked to anxiety and autistic behaviors. The understanding of the neurobiology of FXS has led to the development of targeted treatments for the core behavioral features of FXS, which include social deficits, inattention, and anxiety. These symptoms are also observed in individuals with autism and other neurodevelopmental disorders, therefore the targeted treatments for FXS are leading the way in the treatment of other neurodevelopmental syndromes and autism. The GABAergic system in FXS represents a target for new treatments. Herein, we discuss the animal and human trials of GABAergic treatment in FXS. Arbaclofen and ganaxolone have been used in individuals with FXS. Other potential GABAergic treatments, such as riluzole, gaboxadol, tiagabine, and vigabatrin, will be also discussed. Further studies are needed to determine the safety and efficacy of GABAergic treatments for FXS.

Modelling fragile X syndrome in the laboratory setting: A behavioral perspective

From wings to whiskers to stem cells: why every model matters in fragile X syndrome research

Modeling Fragile X Syndrome: Characterizing Fmr1 Gene Knockout Mice across Genotype, Behavior, and Morphology

Proteomics insights into fragile X syndrome: Unraveling molecular mechanisms and therapeutic avenues

New Targeted Treatments for Fragile X Syndrome

Challenges in developing therapies in fragile X syndrome: how the FXLEARN trial can guide research

Behavioral, neurotransmitter and transcriptomic analyses in male and female Fmr1 KO mice

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Adaptive group behavior of Fragile X mice in unfamiliar environments

Across Dimensions: Developing 2D and 3D Human iPSC-Based Models of Fragile X Syndrome

Developmental Impairments of Synaptic Refinement in the Thalamus of a Mouse Model of Fragile X Syndrome

Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments

Novel fragile X syndrome 2D and 3D brain models based on human isogenic FMRP-KO iPSCs

State‐of‐the‐art therapies for fragile X syndrome

Epigenetic insights into Fragile X Syndrome

Dysregulation of BMP, Wnt, and Insulin Signaling in Fragile X Syndrome

Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously

Hyperexcitability and Homeostasis in Fragile X Syndrome

Using a Combination of Novel Research Tools to Understand Social Interaction in the Drosophila melanogaster Model for Fragile X Syndrome

Fragile X Syndrome Patient–Derived Neurons Developing in the Mouse Brain Show FMR1-Dependent Phenotypes